Home › Companies › ACADIA PHARMACEUTICALS INC. › 2023-2024

ACADIA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ACADIA PHARMACEUTICALS INC.’s Form 8-K, filed 2024-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
306Asset managers
2,108Fund votes
2024-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ACADIA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ACADIA PHARMACEUTICALS INC.

These tallies are ACADIA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ACADIA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-05-29
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Julian C. Baker	125,520,719	--	--	15,262,794	10,293,742	Majority: yes
Elect Director: Stephen R. Biggar, M.D., Ph.D.	128,641,034	--	--	12,142,479	10,293,742	Majority: yes
Elect Director: Daniel B. Soland	124,834,854	--	--	15,948,659	10,293,742	Majority: yes
In addition to the election of three Class II directors, the following matters were submitted to a vote of the stockholders at the 2024 Annual Meeting:	132,994,018	7,639,777	149,718	--	10,293,742	Majority: yes

Source: ACADIA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-05-29 — read the filing on EDGAR.

How asset managers voted at the ACADIA PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 306 asset managers that disclosed a ACADIA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ACADIA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.

COMPENSATION

Combines 11 wordings of this item as funds reported it.

95% fund support · no official result

FOR 95%

The 296 asset managers below cast 95% of the shares they voted on this item FOR (142,044,657 for, 6,989,298 against).

FOR: 142,044,657 (95.3%)AGAINST: 6,989,298 (4.7%)ABSTAIN: 13,190 (0.0%)NOT VOTED: 1,545 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
BAKER BROS. ADVISORS LP	42,801,108	0	For
Vanguard	13,739,446	0	For
BlackRock	10,187,094	66,861	For
RTW INVESTMENTS, LP	10,073,432	0	For
State Street	8,836,217	1,815	For
Fidelity	8,361,164	0	For
T. Rowe Price	6,638,296	0	For
EcoR1 Capital, LLC	4,403,906	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,796,028	0	For
Charles Schwab	2,490,671	0	For
Palo Alto Investors LP	2,418,841	0	For
JUPITER ASSET MANAGEMENT LTD	1,835,174	0	For
DE Shaw	1,792,865	0	For
WEATHERBIE CAPITAL, LLC	0	1,789,707	Against
Putnam	1,489,848	0	For
John Hancock	1,471,780	0	For
First Trust	1,441,812	0	For
EMERALD MUTUAL FUND ADVISERS TRUST	1,250,229	0	For
Northern Trust	1,136,456	0	For
Prudential/PGIM	236,944	812,060	Against
EMERALD ADVISERS, LLC	944,563	0	For
AMERIPRISE FINANCIAL INC	863,278	0	For
Finepoint Capital LP	840,453	0	For
CANADA PENSION PLAN INVESTMENT BOARD	812,100	0	For
ALGER FUNDS	0	811,173	Against

Showing the 25 largest of 296 asset managers. See all 296 in the interactive database.

2. TO APPROVE THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.

COMPENSATION

Combines 3 wordings of this item as funds reported it.

90% fund support · no official result

FOR 90%10%

The 86 asset managers below cast 90% of the shares they voted on this item FOR (38,746,244 for, 4,173,102 against).

FOR: 38,746,244 (90.3%)AGAINST: 4,173,102 (9.7%)

Largest asset managers voting on “TO APPROVE THE COMPANY'S 2024 EQUITY INCENTIVE PLAN.” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	13,399,567	0	For
BlackRock	5,623,329	0	For
Fidelity	4,690,384	0	For
State Street	7,387	3,238,155	Against
T. Rowe Price	2,825,481	0	For
Palo Alto Investors LP	2,418,841	0	For
First Trust	1,432,341	0	For
Charles Schwab	1,245,166	0	For
ALGER FUNDS	811,173	0	For
FINANCIAL INVESTORS TRUST	659,335	0	For
Prudential/PGIM	236,944	207,000	For
Principal	441,986	0	For
TIAA	433,232	0	For
John Hancock	389,237	0	For
Equitable	347,102	0	For
Putnam	0	272,658	Against
Waddell & Reed	241,693	0	For
Direxion Shares ETF Trust	236,172	0	For
Jackson National	76,582	153,348	Against
QUANTITATIVE MASTER SERIES LLC	228,598	0	For
Invesco	219,834	0	For
Voya	198,359	0	For
LIBERTY ALL STAR GROWTH FUND INC.	167,222	0	For
JPMorgan	157,083	0	For
Exchange Place Advisors Trust	144,570	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

3. To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Julian C. Baker

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 125,520,719WITHHELD: 15,262,794

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Julian C. Baker”): 125,520,719 for, 15,262,794 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,959,736 outstanding shares: 76% for, 9% withheld (85% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (32,196,580 for, 0 against).

FOR 79%ABSTAIN 21%

FOR: 32,196,580 (79.5%)ABSTAIN: 8,304,428 (20.5%)

Largest asset managers voting on “To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Juli” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,399,567	0	For
BlackRock	5,623,329	0	For
Fidelity	4,690,384	0	For
State Street	7,547	3,237,995	Abstain
T. Rowe Price	0	2,825,481	Abstain
First Trust	1,432,341	0	For
Charles Schwab	1,245,166	0	For
ALGER FUNDS	811,173	0	For
FINANCIAL INVESTORS TRUST	0	659,335	Abstain
Prudential/PGIM	207,000	236,944	Abstain
Principal	14,631	427,355	Abstain
TIAA	433,232	0	For
John Hancock	352,485	36,752	For
Equitable	334,440	12,662	For
Putnam	272,658	0	For
Waddell & Reed	0	241,693	Abstain
Direxion Shares ETF Trust	236,172	0	For
Jackson National	229,930	0	For
QUANTITATIVE MASTER SERIES LLC	228,598	0	For
Invesco	0	219,834	Abstain
Voya	198,359	0	For
LIBERTY ALL STAR GROWTH FUND INC.	167,222	0	For
JPMorgan	157,083	0	For
Exchange Place Advisors Trust	144,570	0	For
Lincoln Financial	40,829	100,900	Abstain

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

4. To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Daniel B. Soland

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 124,834,854WITHHELD: 15,948,659

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Daniel B. Soland”): 124,834,854 for, 15,948,659 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,959,736 outstanding shares: 76% for, 10% withheld (85% of the company cast a for/withheld vote).

The 84 asset managers below cast 100% of the shares they voted on this item FOR (33,173,936 for, 0 against).

FOR 82%ABSTAIN 18%

FOR: 33,173,936 (82.0%)ABSTAIN: 7,267,072 (18.0%)

Largest asset managers voting on “To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Dani” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,399,567	0	For
BlackRock	5,623,329	0	For
Fidelity	4,690,384	0	For
State Street	3,244,775	767	For
T. Rowe Price	0	2,825,481	Abstain
First Trust	1,432,341	0	For
Charles Schwab	0	1,245,166	Abstain
ALGER FUNDS	0	811,173	Abstain
FINANCIAL INVESTORS TRUST	0	659,335	Abstain
Prudential/PGIM	207,000	236,944	Abstain
Principal	14,345	427,641	Abstain
TIAA	433,232	0	For
John Hancock	352,485	36,752	For
Equitable	189,860	157,242	For
Putnam	272,658	0	For
Waddell & Reed	241,693	0	For
Direxion Shares ETF Trust	236,172	0	For
Jackson National	229,930	0	For
QUANTITATIVE MASTER SERIES LLC	228,598	0	For
Invesco	0	219,834	Abstain
Voya	198,359	0	For
LIBERTY ALL STAR GROWTH FUND INC.	167,222	0	For
JPMorgan	157,083	0	For
Exchange Place Advisors Trust	0	144,570	Abstain
Lincoln Financial	141,729	0	For

Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.

5. To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Stephen R. Biggar, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 128,641,034WITHHELD: 12,142,479

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephen R. Biggar, M.D., Ph.D.”): 128,641,034 for, 12,142,479 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,959,736 outstanding shares: 78% for, 7% withheld (85% of the company cast a for/withheld vote).

The 84 asset managers below cast 100% of the shares they voted on this item FOR (35,152,984 for, 0 against).

FOR 87%13%

FOR: 35,152,984 (86.9%)ABSTAIN: 5,288,024 (13.1%)

Largest asset managers voting on “To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Step” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,399,567	0	For
BlackRock	5,623,329	0	For
Fidelity	4,690,384	0	For
State Street	3,244,263	1,279	For
T. Rowe Price	0	2,825,481	Abstain
First Trust	1,432,341	0	For
Charles Schwab	1,245,166	0	For
ALGER FUNDS	0	811,173	Abstain
FINANCIAL INVESTORS TRUST	0	659,335	Abstain
Prudential/PGIM	207,000	236,944	Abstain
Principal	14,631	427,355	Abstain
TIAA	433,232	0	For
John Hancock	352,485	36,752	For
Equitable	334,440	12,662	For
Putnam	272,658	0	For
Waddell & Reed	241,693	0	For
Direxion Shares ETF Trust	236,172	0	For
Jackson National	229,930	0	For
QUANTITATIVE MASTER SERIES LLC	228,598	0	For
Invesco	219,834	0	For
Voya	198,359	0	For
LIBERTY ALL STAR GROWTH FUND INC.	167,222	0	For
JPMorgan	157,083	0	For
Exchange Place Advisors Trust	144,570	0	For
Lincoln Financial	141,729	0	For

Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.

6. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 84 asset managers below cast 99.9% of the shares they voted on this item FOR (40,485,227 for, 1,088 against).

FOR: 40,485,227 (100.0%)AGAINST: 1,088 (0.0%)ABSTAIN: 12,690 (0.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	13,399,567	0	For
BlackRock	5,623,329	0	For
Fidelity	4,690,384	0	For
State Street	3,245,030	512	For
T. Rowe Price	2,825,481	0	For
First Trust	1,432,341	0	For
Charles Schwab	1,245,166	0	For
ALGER FUNDS	811,173	0	For
FINANCIAL INVESTORS TRUST	659,335	0	For
Prudential/PGIM	443,944	0	For
Principal	441,986	0	For
TIAA	433,232	0	For
John Hancock	389,237	0	For
Equitable	347,102	0	For
Putnam	272,658	0	For
Waddell & Reed	241,693	0	For
Direxion Shares ETF Trust	236,172	0	For
Jackson National	229,930	0	For
QUANTITATIVE MASTER SERIES LLC	228,598	0	For
Invesco	219,834	0	For
Voya	198,359	0	For
LIBERTY ALL STAR GROWTH FUND INC.	167,222	0	For
JPMorgan	157,083	0	For
Exchange Place Advisors Trust	144,570	0	For
Lincoln Financial	141,729	0	For

Showing the 25 largest of 84 asset managers. See all 84 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

45.6% fund support · no official result

FOR 45.6%AGAINST 54.4%

The 6 asset managers below cast 45.6% of the shares they voted on this item FOR (422,362 for, 503,798 against).

FOR: 422,362 (45.6%)AGAINST: 503,798 (54.4%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
NORDEA INVESTMENT MANAGEMENT AB	0	321,450	Against
JPMorgan	274,748	0	For
APG Asset Management US Inc.	0	182,348	Against
EFG Asset Management (North America) Corp.	76,660	0	For
ALGERT GLOBAL LLC	68,951	0	For
Virtus	2,003	0	For

8. Approval of the 2024 Equity Incentive Plan

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (70,954 for, 0 against).

FOR: 70,954 (100.0%)

Largest asset managers voting on “Approval of the 2024 Equity Incentive Plan” at ACADIA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ALGERT GLOBAL LLC	68,951	0	0	0	For
Virtus	2,003	0	0	0	For

Largest ACADIA PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of ACADIA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 164,959,736 shares outstanding at the time of that meeting.

Top ACADIA PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	25.95%
2	Vanguard	8.33%
3	BlackRock	6.22%
4	RTW INVESTMENTS, LP	6.11%
5	State Street	5.36%
6	Fidelity	5.07%
7	T. Rowe Price	4.02%
8	EcoR1 Capital, LLC	2.67%
9	GEODE CAPITAL MANAGEMENT, LLC	1.69%
10	Charles Schwab	1.51%

Reported ACADIA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ACADIA PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Baker Bros. Advisors LP	26.21%	DEF14A
Julian C. Baker	26.21%	DEF14A
Stephen R. Biggar	26.15%	DEF14A
BlackRock	12.29%	13F
Vanguard Group	9.20%	13F
RTW Investments LP	6.82%	DEF14A
State Street	3.64%	13F
T. Rowe Price	2.42%	13F
Geode Capital	1.69%	13F
D.E. Shaw	1.60%	13F

Percentages above are of 164,959,736 shares outstanding, as reported by ACADIA PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACADIA PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ACADIA PHARMACEUTICALS INC.'s shareholder meeting held 2024-05-29, in the 2023-2024 proxy season, 306 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,108 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ACADIA PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ACADIA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.